Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lale Erdem-Eraslan

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
British Journal of Haematology|November 17, 2017
Inter-individual variability in phospholipid-dependent interference of C-reactive protein on activated partial thromboplastin timeLale Erdem-Eraslan, Jacques J H Hens, André P van Rossum, et al.
European Journal of Cancer (Oxford, England : 1990)|March 11, 2015
Mutation specific functions of EGFR result in a mutation-specific downstream pathway activationLale Erdem-Eraslan, Ya Gao, Nanne K Kloosterhof, et al.
Journal of Neuro-Oncology|February 20, 2015
Tumor-specific mutations in low-frequency genes affect their functional propertiesLale Erdem-Eraslan, Daphne Heijsman, Maurice de Wit, et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry|March 20, 2022
Awareness of drug laboratory test interactions is important for prevention of unnecessary additional diagnostics: An exampleJasmijn A van Balveren, Lale Erdem-Eraslan, Wilhelmine P H G Verboeket-van de Venne, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 17, 2013
MGMT-STP27 methylation status as predictive marker for response to PCV in anaplastic Oligodendrogliomas and Oligoastrocytomas. A report from EORTC study 26951Martin J van den Bent, Lale Erdem-Eraslan, Ahmed Idbaih, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 28, 2012
Intrinsic molecular subtypes of glioma are prognostic and predict benefit from adjuvant procarbazine, lomustine, and vincristine chemotherapy in combination with other prognostic factors in anaplastic oligodendroglial brain tumors: a report from EORTC study 26951Lale Erdem-Eraslan, Lonneke A Gravendeel, Johan de Rooi, et al.
Clinical Chemistry and Laboratory Medicine|October 18, 2018
Impact of interactions between drugs and laboratory test results on diagnostic test interpretation - a systematic reviewJasmijn A van Balveren, Wilhelmine P H G Verboeket-van de Venne, Lale Erdem-Eraslan, et al.
Diagnosis (Berlin, Germany)|February 13, 2019
Diagnostic error as a result of drug-laboratory test interactionsJasmijn A van Balveren, Wilhelmine P H G Verboeket-van de Venne, Lale Erdem-Eraslan, et al.
Clinical Chemistry and Laboratory Medicine|February 20, 2022
Added value of drug-laboratory test interaction alerts in test result authorisationJasmijn A van Balveren, Wilhelmine P H G Verboeket-van de Venne, Carine J M Doggen, et al.
Clinical Chemistry and Laboratory Medicine|November 9, 2021
Real-time monitoring of drug laboratory test interactions: a proof of conceptJasmijn A van Balveren, Wilhelmine P H G Verboeket-van de Venne, Carine J M Doggen, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
British Journal of Haematology|November 17, 2017
Inter-individual variability in phospholipid-dependent interference of C-reactive protein on activated partial thromboplastin timeLale Erdem-Eraslan, Jacques J H Hens, André P van Rossum, et al.
European Journal of Cancer (Oxford, England : 1990)|March 11, 2015
Mutation specific functions of EGFR result in a mutation-specific downstream pathway activationLale Erdem-Eraslan, Ya Gao, Nanne K Kloosterhof, et al.
Journal of Neuro-Oncology|February 20, 2015
Tumor-specific mutations in low-frequency genes affect their functional propertiesLale Erdem-Eraslan, Daphne Heijsman, Maurice de Wit, et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry|March 20, 2022
Awareness of drug laboratory test interactions is important for prevention of unnecessary additional diagnostics: An exampleJasmijn A van Balveren, Lale Erdem-Eraslan, Wilhelmine P H G Verboeket-van de Venne, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 17, 2013
MGMT-STP27 methylation status as predictive marker for response to PCV in anaplastic Oligodendrogliomas and Oligoastrocytomas. A report from EORTC study 26951Martin J van den Bent, Lale Erdem-Eraslan, Ahmed Idbaih, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 28, 2012
Intrinsic molecular subtypes of glioma are prognostic and predict benefit from adjuvant procarbazine, lomustine, and vincristine chemotherapy in combination with other prognostic factors in anaplastic oligodendroglial brain tumors: a report from EORTC study 26951Lale Erdem-Eraslan, Lonneke A Gravendeel, Johan de Rooi, et al.
Clinical Chemistry and Laboratory Medicine|October 18, 2018
Impact of interactions between drugs and laboratory test results on diagnostic test interpretation - a systematic reviewJasmijn A van Balveren, Wilhelmine P H G Verboeket-van de Venne, Lale Erdem-Eraslan, et al.
Diagnosis (Berlin, Germany)|February 13, 2019
Diagnostic error as a result of drug-laboratory test interactionsJasmijn A van Balveren, Wilhelmine P H G Verboeket-van de Venne, Lale Erdem-Eraslan, et al.
Clinical Chemistry and Laboratory Medicine|February 20, 2022
Added value of drug-laboratory test interaction alerts in test result authorisationJasmijn A van Balveren, Wilhelmine P H G Verboeket-van de Venne, Carine J M Doggen, et al.
Clinical Chemistry and Laboratory Medicine|November 9, 2021
Real-time monitoring of drug laboratory test interactions: a proof of conceptJasmijn A van Balveren, Wilhelmine P H G Verboeket-van de Venne, Carine J M Doggen, et al.
Pageof 2